History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium

Minlikeeva AN, Freudenheim JL, Eng KH, Cannioto RA, Friel G, Szender JB, Segal B, Odunsi K, Mayor P, Diergaarde B, Zsiros E, Kelemen LE, Kobel M, Steed H, Defazio A, Jordan SJ, Fasching P, Beckmann M, Risch HA, Rossing MA, Doherty JA, Chang-Claude J, Goodman MT, Doerk T, Edwards R, Modugno F, Ness RB, Matsuo K, Mizuno M, Karlan BY, Goode EL, Kjaer SK, Hogdall E, Schildkraut JM, Terry KL, Cramer DW, Bandera EV, Paddock LE, Kiemeney LA, Massuger LFAG, Sutphen R, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Kupryjanczyk J, Jensen A, Webb PM, Moysich KB (2017)

Publication Type: Journal article

Publication year: 2017

Journal

Book Volume: 26

Pages Range: 1470-1473

Journal Issue: 9

DOI: 10.1158/1055-9965.EPI-17-0367

Abstract

Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients.Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes.Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced).Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival.Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. Cancer Epidemiol Biomarkers Prev; 26(9); 1470-3. ©2017 AACR.

Authors with CRIS profile

Involved external institutions

Independent Health United States (USA) (US) University of Pittsburgh United States (USA) (US) Radboud University Nijmegen Netherlands (NL) Aichi Cancer Center Research Institute Japan (JP) University of Sydney (USYD) Australia (AU) Dartmouth College United States (USA) (US) Roswell Park Cancer Institute United States (USA) (US) QIMR Berghofer Medical Research Institute (früher: the Queensland Institute of Medical Research) Australia (AU) University of Virginia (UVA) United States (USA) (US) Rutgers Cancer Institute of New Jersey United States (USA) (US) University College London (UCL) United Kingdom (GB) Yale University United States (USA) (US) University of California Irvine United States (USA) (US) University of Calgary Canada (CA) University of Texas MD Anderson Cancer Center United States (USA) (US) University of New South Wales (UNSW) Australia (AU) Brigham and Women's Hospital (BWH) United States (USA) (US) University of Michigan United States (USA) (US) Cedars-Sinai Medical Center United States (USA) (US) Royal Alexandra Hospital (RAH) Canada (CA) Danish Cancer Society Denmark (DK) Deutsches Krebsforschungszentrum (DKFZ) Germany (DE) Maria Skłodowska-Curie Institute of Oncology / Centrum Onkologii–Instytut im. Marii Skłodowskiej-Curie w Warszawie Poland (PL) New Jersey, Department of Health United States (USA) (US) University of Southern California (USC) United States (USA) (US) Mayo Clinic United States (USA) (US) University of South Florida (USF) United States (USA) (US) University at Buffalo. State University of New York United States (USA) (US) Medical University of South Carolina (MUSC) United States (USA) (US) Fred Hutchinson Cancer Research Center Canada (CA) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE)

How to cite

APA:

Minlikeeva, A.N., Freudenheim, J.L., Eng, K.H., Cannioto, R.A., Friel, G., Szender, J.B.,... Moysich, K.B. (2017). History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention, 26(9), 1470-1473. https://dx.doi.org/10.1158/1055-9965.EPI-17-0367

MLA:

Minlikeeva, Albina N., et al. "History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium." Cancer Epidemiology Biomarkers & Prevention 26.9 (2017): 1470-1473.

BibTeX: Download